Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 45779A846 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Marshall Wace, LLP 13G/A | 10.0% |
11/14/2025
Event 9/30/2025
|
||
|
Nantahala Capital Management, LLC
13G/A
|
10.0% |
5/15/2026
Event 3/31/2026
|
||
| Nantahala Capital Management, LLC | 10.0% | |||
| Wilmot B. Harkey | 10.0% | |||
| Daniel Mack | 10.0% | |||
|
Rosalind Advisors, Inc.
13G/A
|
9.2% |
2/11/2026
Event 12/31/2025
|
||
| Rosalind Advisors, Inc. | 9.2% | |||
| Salamon Steven A J | 9.2% | |||
| Aharon Gil | 9.2% | |||
| Rosalind Master Fund L.P. | 8.3% | |||
| Rosalind Opportunities Fund I L.P. | 1.0% | |||
| Michael A. Lawless 13D | 8.6% |
10/29/2025
Event 6/26/2025
|
||
|
Aberdeen Group plc
13G/A
|
7.5% |
2/2/2026
Event 12/31/2025
|
||
| Aberdeen Group plc | 7.5% | |||
| abrdn Inc. | 7.5% | |||
|
Orbimed Advisors LLC
13G
|
7.4% |
2/17/2026
Event 12/31/2025
|
||
| Orbimed Advisors LLC | 7.4% | |||
| OrbiMed Capital GP IX LLC | 6.8% | |||
|
Parkman Healthcare Partners LLC
13G
|
5.8% |
11/14/2025
Event 9/30/2025
|
||
| Parkman Healthcare Partners LLC | 5.8% | |||
| Parkman Healthcare Partners Holdings LP | 5.8% | |||
| Parkman Healthcare Partners Holdings GP LLC | 5.8% | |||
| Martinez Gregory | 5.8% | |||
| Nantahala Capital Partners Limited Partnership 13G/A | 5.7% |
11/14/2025
Event 9/30/2025
|
||
| Marvin Slosman 13D | 5.2% |
4/24/2026
Event 1/22/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Velan Capital Investment Management LP
13G/A
|
4.99% |
5/15/2026
Event 3/31/2026
|
||
| Velan Capital Master Fund LP | 4.99% | |||
| Velan Capital Holdings LLC | 4.99% | |||
| Velan Capital Investment Management LP | 4.99% | |||
| Velan Capital Management LLC | 4.99% | |||
| Morgan Adam | 4.99% | |||
| Venkataraman Balaji | 4.99% | |||
| Craig Shore 13D/A | 3.5% |
10/29/2025
Event 6/26/2025
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 1.00 k | $668.00 |
| 2026 Q2 | 40 | 24.9 M | $17.4 M |
| 2026 Q1 | 35 | 22.8 M | $37.2 M |
| 2025 Q4 | 45 | 23.2 M | $41.2 M |
| 2025 Q3 | 41 | 22.7 M | $54.8 M |
| 2025 Q2 | 38 | 14.1 M | $31.9 M |
| 2025 Q1 | 36 | 12.9 M | $34.7 M |
| 2024 Q4 | 31 | 12.7 M | $33.4 M |
| 2024 Q3 | 29 | 12.4 M | $33.2 M |
| 2024 Q2 | 27 | 14.1 M | $35.1 M |
| 2024 Q1 | 32 | 10.3 M | $24.3 M |
| 2023 Q4 | 31 | 12.5 M | $35.0 M |
| 2023 Q3 | 26 | 8.76 M | $28.7 M |
| 2023 Q2 | 23 | 8.05 M | $20.2 M |
| 2023 Q1 | 15 | 90.0 k | $104 k |
| 2022 Q4 | 18 | 156 k | $137 k |
| 2022 Q3 | 16 | 113 k | $169 k |
| 2022 Q2 | 17 | 130 k | $259 k |
| 2022 Q1 | 19 | 141 k | $457 k |
| 2021 Q4 | 23 | 184 k | $561 k |
| 2021 Q3 | 17 | 170 k | $704 k |
| 2021 Q2 | 16 | 451 k | $2.28 M |